What Novo Nordisk’s Failed Heart-Drug Trial Really Tells Investors

What ZEUS means for Novo’s pipeline and how far investors should apply its result.

I usually write an article once a week. Not because there isn’t much to analyze and share with you. On the contrary - there is plenty to cover - but the fact is that each article takes considerable time and effort to knock out.

But this week, I am making an exception. The minute I read the Novo Nordisk announcement, I knew I was going to be clearing my …